Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
SAN DIEGO, Feb. 23, 2016 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Tuesday, March 8, 2016 at 11:20 a.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.
About Retrophin
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with no approved treatment options, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's marketed products, Chenodal®, Cholbam® and Thiola®.
Retrophin.com
Contact: Chris Cline, CFA Director, Investor Relations 646-564-3680 [email protected]
